Regeneron Pharmaceuticals, Inc. (LON:0R2M)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 37.55B |
| Revenue (ttm) | 10.90B |
| Net Income (ttm) | 3.48B |
| Shares Out | n/a |
| EPS (ttm) | 30.52 |
| PE Ratio | 10.78 |
| Forward PE | 12.66 |
| Dividend | 1.35 (0.27%) |
| Ex-Dividend Date | May 20, 2025 |
| Volume | 2,661 |
| Average Volume | 8,477 |
| Open | 496.00 |
| Previous Close | 495.00 |
| Day's Range | 481.41 - 501.81 |
| 52-Week Range | 485.00 - 1,210.92 |
| Beta | n/a |
| RSI | 29.98 |
| Earnings Date | Aug 1, 2025 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.
Financial numbers in USD Financial StatementsNews
Does the 23andMe Acquisition Make Regeneron a Buy Now?
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Regeneron Pharmaceuticals (NASDAQ: REGN) has outperformed the market over the past 15 years by 10.66% on an annualized basis producing an average annual return of 22.46%. Currently, Regeneron Pharmac...
Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma
First results to be presented in two ASCO oral presentations Data in both combinations demonstrate high response rates TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc....
What Regeneron's Purchase Of 23andMe Means For Your Genetic Privacy
Regeneron Pharmaceuticals announced on Monday it will acquire bankrupt genomics firm 23andMe for $256 million through a bankruptcy auction, promising to maintain ethical standards in handling sensitiv...
Regeneron's 23andMe Steal: Smart Genetics Play That Won't Cure Near-Term Growth Pains
Regeneron Pharmaceuticals, Inc. (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)
23andMe sale grafts a happy ending on to a glum tale
Being spliced on to Regeneron will free the genetic testing company from its fatal dependence on sporadic revenue
Viz.ai Announces Collaboration With Sanofi and Regeneron to Improve Management and Care of Chronic Obstructive Pulmonary Disease (COPD)
SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a multi-year partnership with Sanofi (NASDAQ: SNY), an innov...
Bankrupt DNA testing company 23andMe to be acquired by Regeneron for $256 million
Regeneron Pharmaceuticals is set to acquire 23andMe for $256 million following its bankruptcy filing due to declining demand and a significant data breach in 2023. The acquisition excludes Lemonaid He...
Regeneron acquires bankrupt 23andMe, pledges ethical use of genetic data
Regeneron Pharmaceuticals announced on Monday that it will acquire the genetic testing business and most assets of 23andMe for $256 million in cash. The transaction, which excludes 23andMe's telehealt...
Regeneron buys 23andMe for $256m after bankruptcy
Sale of genetic testing company raises concerns about privacy of 23andMe’s 15 million customers.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2206338240-bedb93720ad24fce94951c160cf3faac.jpg)
Regeneron Buys 23andMe in Bankruptcy Auction
Regeneron Pharmaceuticals agreed to buy DNA testing company 23andMe in a bankruptcy court auction, the company said Monday.
Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions
It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly handed over the samples to completely different owners.
OraSure rises as seen benefitting from 23andMe/Regeneron deal
OraSure Technologies gains on news of Regeneron's acquisition of 23andMe assets, solidifying a key partnership. Read more here.
Regeneron Is Buying 23andMe. The Deal Is a Head-Scratcher.
Regeneron Pharmaceuticals to buy bankrupt 23andMe in $256M deal
Genetic testing company 23andMe filed for Chapter 11 bankruptcy protection in March. Regeneron Pharmaceuticals announced it would buy "substantially all" of 23andMe's assets.
Struggling DNA testing firm 23andMe to be bought for $256m
It said new buyers Regeneron had committed to protect user data as part of the deal.
Pharma giant Regeneron to buy 23andMe and its customers’ data for $256M
23andMe was sold by bankruptcy auction, a year after the company had a massive data breach.
Cramer's Stop Trading: Regeneron
Jim Camer breaks down why he's keeping an eye on shares of Regeneron.
Bankrupt DNA testing firm 23andMe to be purchased for $256m
Drugmaker Regeneron Pharmaceuticals will buy the genetic testing firm through a bankruptcy auction Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe Holding for $256m through a...
Drugmaker Regeneron to acquire 23andMe out of bankruptcy
The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices to protect customer data.
Cramer's Stop Trading: Regeneron
Jim Camer breaks down why he's keeping an eye on shares of Regeneron.
Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million
Regeneron is acquiring "substantially all" of 23andMe's assets for $256 million following a bankruptcy auction.
23andMe sold out of bankruptcy to Regeneron
Drugmaker’s takeover could raise privacy concerns among genetics start-up’s 15mn users
23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.
Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles including a data breach.